The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy Leriglitazone was well tolerated, and significant benefit was shown through ... 20/01/2023
Leriglitazone’s clinical proof of concept data in Friedreich’s Ataxia published in Neurology Genetics Published data highlights therapeutic potential to treat patients with this ... 29/11/2022
Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe The companies enter into a license agreement for the European ... 10/11/2022
15 Mar 2022 - 20 Mar 2022 AD/PD2022 International Conference on Alzheimer's and Parkinson's Diseases VIRTUAL
17 Oct 2021 - 19 Oct 2021 ANA 2021 - 16th Annual Meeting of the American Neurological Association VIRTUAL
Headquarters https://www.minoryx.com/content/imgs/mail/logo.png Av. Ernest Lluch 32 08302 Mataró (Barcelona) Spain
Belgian R&D Site https://www.minoryx.com/content/imgs/mail/logo.png Ave. Jean Mermoz 32 6041 Gosselies (Charleroi) Belgium